- Home
- CYCU vs ASBP Comparison
CYCU vs ASBP Comparison
Compare CYCU & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYCU | ASBP |
|---|---|---|
| Founded | 2017 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 7.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CYCU | ASBP |
|---|---|---|
| Price | $1.68 | $1.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 174.4K | ★ 1.6M |
| Earning Date | 04-17-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,667,874.00 | $1,941.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.62 | $1.20 |
| 52 Week High | $892.86 | $632.00 |
Technical Indicators
Market Signals| Indicator | CYCU | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 31.20 | 53.17 |
| Support Level | $1.71 | $1.20 |
| Resistance Level | $2.18 | $2.45 |
| Average True Range (ATR) | 0.21 | 0.28 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 19.55 | 10.39 |
Price Performance
Historical ComparisonAbout CYCU Cycurion Inc.
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.